Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
8.55(c) 8.87(c) 9.01(c) 9(c) 8.98 Last
253 559 217 985 139 262 187 976 96 110 Volume
-4.15% +3.74% +1.58% -0.11% -0.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 45,7 M - -
Net income 2021 -69,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,39x
Yield 2021 -
Sales 2022 19,2 M - -
Net income 2022 -105 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,49x
Yield 2022 -
Capitalization 461 M 461 M -
Capi. / Sales 2021 10,1x
Capi. / Sales 2022 24,0x
Nbr of Employees 128
Free-Float 81,7%
More Financials
Company
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. It focuses on specific cell types, both immune and non-immune, within tumors, and targets and identifies related biomarkers designed... 
More about the company
Ratings of Jounce Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about JOUNCE THERAPEUTICS, INC.
10/07JOUNCE THERAPEUTICS : Initiates Enrollment of Phase 1 Trial Cohorts of JTX-8064
MT
10/07JOUNCE THERAPEUTICS : Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monother..
AQ
10/07Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monothe..
CI
09/15JOUNCE THERAPEUTICS : Departures of Directors or Certain Officers; Election of Directors; ..
PU
09/15JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/15Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
GL
09/15Jounce Therapeutics, Inc. Announces Board Changes
CI
09/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/14JOUNCE THERAPEUTICS : Raymond James Upgrades Jounce Therapeutics to Outperform From Market..
MT
09/02Jounce Therapeutics to Present at Upcoming Investor Conferences in September
GL
08/05JOUNCE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/05Jounce Therapeutics Reports Second Quarter 2021 Financial Results
GL
08/05JOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
08/05Jounce Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
CI
07/29Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Confer..
GL
More news
News in other languages on JOUNCE THERAPEUTICS, INC.
2018Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on JOUNCE THERAPEUTICS, INC.
More recommendations
Chart JOUNCE THERAPEUTICS, INC.
Duration : Period :
Jounce Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOUNCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 9,00 $
Average target price 14,50 $
Spread / Average Target 61,1%
EPS Revisions
Managers and Directors
Richard Murray President, Chief Executive Officer & Director
Kimberlee Cobleigh Drapkin Chief Financial Officer & Treasurer
Perry A. Karsen Chairman
Elizabeth G. Trehu Chief Medical Officer
Stephen Farrand Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOUNCE THERAPEUTICS, INC.28.57%461
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610